Annual EBITDA:
-$493.48M-$36.80M(-8.06%)Summary
- As of today, CYTK annual EBITDA is -$493.48 million, with the most recent change of -$36.80 million (-8.06%) on December 31, 2024.
- During the last 3 years, CYTK annual EBITDA has fallen by -$309.78 million (-168.63%).
- CYTK annual EBITDA is now -1919.36% below its all-time high of $27.12 million, reached on December 31, 2009.
Performance
CYTK EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
-$164.08M-$54.85M(-50.22%)Summary
- As of today, CYTK quarterly EBITDA is -$164.08 million, with the most recent change of -$54.85 million (-50.22%) on September 30, 2025.
- Over the past year, CYTK quarterly EBITDA has dropped by -$25.69 million (-18.56%).
- CYTK quarterly EBITDA is now -382.34% below its all-time high of $58.11 million, reached on June 30, 2009.
Performance
CYTK Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$563.28M-$25.69M(-4.78%)Summary
- As of today, CYTK TTM EBITDA is -$563.28 million, with the most recent change of -$25.69 million (-4.78%) on September 30, 2025.
- Over the past year, CYTK TTM EBITDA has dropped by -$52.14 million (-10.20%).
- CYTK TTM EBITDA is now -2015.87% below its all-time high of $29.40 million, reached on September 30, 2009.
Performance
CYTK TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CYTK EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | -8.1% | -18.6% | -10.2% |
| 3Y3 Years | -168.6% | -54.3% | -167.6% |
| 5Y5 Years | -430.4% | -2968.5% | -608.6% |
CYTK EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -168.6% | at low | -54.3% | at low | -167.6% | at low |
| 5Y | 5-Year | -468.6% | at low | -2968.5% | at low | -608.6% | at low |
| All-Time | All-Time | -1919.4% | at low | -382.3% | at low | -2015.9% | at low |
CYTK EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2025 | - | -$164.08M(-50.2%) | -$563.28M(-4.8%) |
| Jun 2025 | - | -$109.22M(+28.8%) | -$537.60M(+3.3%) |
| Mar 2025 | - | -$153.33M(-12.2%) | -$556.14M(-5.6%) |
| Dec 2024 | -$493.48M(-8.1%) | -$136.66M(+1.3%) | -$526.72M(-3.0%) |
| Sep 2024 | - | -$138.39M(-8.3%) | -$511.14M(-3.6%) |
| Jun 2024 | - | -$127.77M(-3.1%) | -$493.16M(-1.8%) |
| Mar 2024 | - | -$123.90M(-2.3%) | -$484.66M(-0.5%) |
| Dec 2023 | -$456.68M(-37.6%) | -$121.08M(-0.6%) | -$482.44M(+0.7%) |
| Sep 2023 | - | -$120.41M(-1.0%) | -$485.65M(-3.0%) |
| Jun 2023 | - | -$119.26M(+2.0%) | -$471.59M(-30.6%) |
| Mar 2023 | - | -$121.69M(+2.1%) | -$361.20M(-14.4%) |
| Dec 2022 | -$331.99M(-80.7%) | -$124.29M(-16.9%) | -$315.80M(-50.0%) |
| Sep 2022 | - | -$106.35M(-1098.7%) | -$210.53M(-25.7%) |
| Jun 2022 | - | -$8.87M(+88.4%) | -$167.51M(+21.3%) |
| Mar 2022 | - | -$76.29M(-301.2%) | -$212.89M(-20.5%) |
| Dec 2021 | -$183.71M(-111.7%) | -$19.02M(+70.0%) | -$176.68M(+8.7%) |
| Sep 2021 | - | -$63.33M(-16.7%) | -$193.60M(-55.4%) |
| Jun 2021 | - | -$54.25M(-35.4%) | -$124.54M(-21.8%) |
| Mar 2021 | - | -$40.07M(-11.5%) | -$102.23M(-11.0%) |
| Dec 2020 | -$86.78M(+6.7%) | -$35.94M(-728.3%) | -$92.11M(-15.9%) |
| Sep 2020 | - | $5.72M(+117.9%) | -$79.49M(+26.9%) |
| Jun 2020 | - | -$31.94M(-6.6%) | -$108.80M(-5.3%) |
| Mar 2020 | - | -$29.95M(-28.5%) | -$103.30M(-5.9%) |
| Dec 2019 | -$93.04M(-11.4%) | -$23.32M(+1.2%) | -$97.57M(-1.6%) |
| Sep 2019 | - | -$23.59M(+10.8%) | -$96.04M(-6.6%) |
| Jun 2019 | - | -$26.44M(-9.1%) | -$90.09M(-4.2%) |
| Mar 2019 | - | -$24.23M(-11.3%) | -$86.45M(+1.4%) |
| Dec 2018 | -$83.49M(+23.3%) | -$21.78M(-23.4%) | -$87.68M(+13.9%) |
| Sep 2018 | - | -$17.65M(+22.6%) | -$101.84M(+9.2%) |
| Jun 2018 | - | -$22.80M(+10.5%) | -$112.16M(+1.7%) |
| Mar 2018 | - | -$25.46M(+29.2%) | -$114.12M(-2.4%) |
| Dec 2017 | -$108.87M(-647.3%) | -$35.94M(-28.5%) | -$111.50M(-64.8%) |
| Sep 2017 | - | -$27.97M(-13.0%) | -$67.65M(-1123.1%) |
| Jun 2017 | - | -$24.75M(-8.4%) | -$5.53M(-242.4%) |
| Mar 2017 | - | -$22.83M(-388.5%) | $3.88M(-74.0%) |
| Dec 2016 | $19.89M(+154.3%) | $7.91M(-76.8%) | $14.93M(+905.7%) |
| Sep 2016 | - | $34.14M(+322.6%) | -$1.85M(+95.9%) |
| Jun 2016 | - | -$15.34M(-30.2%) | -$44.74M(-12.3%) |
| Mar 2016 | - | -$11.78M(-32.9%) | -$39.84M(-8.2%) |
| Dec 2015 | -$36.64M(-158.9%) | -$8.87M(-1.5%) | -$36.82M(-89.9%) |
| Sep 2015 | - | -$8.74M(+16.3%) | -$19.39M(-17.4%) |
| Jun 2015 | - | -$10.44M(-19.1%) | -$16.52M(-15.0%) |
| Mar 2015 | - | -$8.76M(-202.4%) | -$14.36M(-0.7%) |
| Dec 2014 | -$14.16M(+57.5%) | $8.56M(+245.7%) | -$14.26M(+12.5%) |
| Sep 2014 | - | -$5.87M(+29.1%) | -$16.30M(+28.9%) |
| Jun 2014 | - | -$8.29M(+4.4%) | -$22.94M(+22.5%) |
| Mar 2014 | - | -$8.66M(-232.9%) | -$29.60M(+11.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2013 | -$33.28M(+16.3%) | $6.52M(+152.1%) | -$33.46M(+34.8%) |
| Sep 2013 | - | -$12.51M(+16.3%) | -$51.34M(-5.3%) |
| Jun 2013 | - | -$14.95M(-19.4%) | -$48.77M(-14.4%) |
| Mar 2013 | - | -$12.52M(-10.2%) | -$42.64M(-6.8%) |
| Dec 2012 | -$39.78M(+14.5%) | -$11.36M(-14.3%) | -$39.92M(-2.3%) |
| Sep 2012 | - | -$9.94M(-12.6%) | -$39.04M(+1.2%) |
| Jun 2012 | - | -$8.82M(+10.0%) | -$39.52M(+10.1%) |
| Mar 2012 | - | -$9.80M(+6.4%) | -$43.95M(+3.4%) |
| Dec 2011 | -$46.52M(+1.8%) | -$10.48M(-0.6%) | -$45.48M(+1.5%) |
| Sep 2011 | - | -$10.41M(+21.5%) | -$46.17M(+3.5%) |
| Jun 2011 | - | -$13.26M(-17.0%) | -$47.85M(-1.2%) |
| Mar 2011 | - | -$11.33M(-1.4%) | -$47.27M(+1.0%) |
| Dec 2010 | -$47.40M(-274.8%) | -$11.17M(+7.6%) | -$47.73M(+1.5%) |
| Sep 2010 | - | -$12.09M(+4.6%) | -$48.47M(-9.9%) |
| Jun 2010 | - | -$12.68M(-7.5%) | -$44.10M(-265.3%) |
| Mar 2010 | - | -$11.79M(+0.9%) | $26.68M(-5.0%) |
| Dec 2009 | $27.12M(+150.8%) | -$11.91M(-54.1%) | $28.09M(-4.5%) |
| Sep 2009 | - | -$7.73M(-113.3%) | $29.40M(+25.0%) |
| Jun 2009 | - | $58.11M(+659.5%) | $23.53M(+147.1%) |
| Mar 2009 | - | -$10.39M(+2.0%) | -$49.99M(+7.7%) |
| Dec 2008 | -$53.43M(+0.4%) | -$10.60M(+22.1%) | -$54.15M(+6.4%) |
| Sep 2008 | - | -$13.60M(+11.7%) | -$57.85M(-1.9%) |
| Jun 2008 | - | -$15.40M(-5.8%) | -$56.78M(-2.9%) |
| Mar 2008 | - | -$14.55M(-1.8%) | -$55.20M(-2.9%) |
| Dec 2007 | -$53.66M(+8.1%) | -$14.30M(-14.1%) | -$53.66M(+3.5%) |
| Sep 2007 | - | -$12.53M(+9.3%) | -$55.63M(+4.7%) |
| Jun 2007 | - | -$13.82M(-6.2%) | -$58.38M(+0.6%) |
| Mar 2007 | - | -$13.01M(+20.1%) | -$58.70M(-0.5%) |
| Dec 2006 | -$58.41M(-40.5%) | -$16.27M(-6.5%) | -$58.41M(-10.0%) |
| Sep 2006 | - | -$15.28M(-8.0%) | -$53.09M(-11.1%) |
| Jun 2006 | - | -$14.14M(-11.2%) | -$47.78M(-8.7%) |
| Mar 2006 | - | -$12.72M(-16.1%) | -$43.97M(-5.8%) |
| Dec 2005 | -$41.57M(-18.2%) | -$10.95M(-9.9%) | -$41.57M(+1.2%) |
| Sep 2005 | - | -$9.97M(+3.5%) | -$42.09M(-0.3%) |
| Jun 2005 | - | -$10.33M(-0.1%) | -$41.95M(-4.0%) |
| Mar 2005 | - | -$10.32M(+10.1%) | -$40.33M(-14.7%) |
| Dec 2004 | -$35.16M(-19.5%) | -$11.47M(-16.8%) | -$35.16M(+45.2%) |
| Sep 2004 | - | -$9.83M(-12.9%) | -$64.21M(-24.1%) |
| Jun 2004 | - | -$8.71M(-69.1%) | -$51.73M(-8.3%) |
| Mar 2004 | - | -$5.15M(+87.3%) | -$47.76M(-0.3%) |
| Dec 2003 | -$29.41M(-39.2%) | -$40.52M(-1632.6%) | -$47.62M(-571.1%) |
| Sep 2003 | - | $2.64M(+155.9%) | -$7.09M(+27.1%) |
| Jun 2003 | - | -$4.73M(+5.5%) | -$9.74M(-94.5%) |
| Mar 2003 | - | -$5.01M | -$5.01M |
| Dec 2002 | -$21.13M(-14.9%) | - | - |
| Dec 2001 | -$18.39M(-33.3%) | - | - |
| Dec 2000 | -$13.79M | - | - |
FAQ
- What is Cytokinetics, Incorporated annual EBITDA?
- What is the all-time high annual EBITDA for Cytokinetics, Incorporated?
- What is Cytokinetics, Incorporated annual EBITDA year-on-year change?
- What is Cytokinetics, Incorporated quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Cytokinetics, Incorporated?
- What is Cytokinetics, Incorporated quarterly EBITDA year-on-year change?
- What is Cytokinetics, Incorporated TTM EBITDA?
- What is the all-time high TTM EBITDA for Cytokinetics, Incorporated?
- What is Cytokinetics, Incorporated TTM EBITDA year-on-year change?
What is Cytokinetics, Incorporated annual EBITDA?
The current annual EBITDA of CYTK is -$493.48M
What is the all-time high annual EBITDA for Cytokinetics, Incorporated?
Cytokinetics, Incorporated all-time high annual EBITDA is $27.12M
What is Cytokinetics, Incorporated annual EBITDA year-on-year change?
Over the past year, CYTK annual EBITDA has changed by -$36.80M (-8.06%)
What is Cytokinetics, Incorporated quarterly EBITDA?
The current quarterly EBITDA of CYTK is -$164.08M
What is the all-time high quarterly EBITDA for Cytokinetics, Incorporated?
Cytokinetics, Incorporated all-time high quarterly EBITDA is $58.11M
What is Cytokinetics, Incorporated quarterly EBITDA year-on-year change?
Over the past year, CYTK quarterly EBITDA has changed by -$25.69M (-18.56%)
What is Cytokinetics, Incorporated TTM EBITDA?
The current TTM EBITDA of CYTK is -$563.28M
What is the all-time high TTM EBITDA for Cytokinetics, Incorporated?
Cytokinetics, Incorporated all-time high TTM EBITDA is $29.40M
What is Cytokinetics, Incorporated TTM EBITDA year-on-year change?
Over the past year, CYTK TTM EBITDA has changed by -$52.14M (-10.20%)